CHEMO PHARMA LABORATORIES LIMITED |
Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
| 66.6 INR | -0.58% |
|
+0.91% | +2.18% |
Valuation
| Fiscal Period: Maart | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 |
|---|---|---|---|---|---|---|
| Capitalization 1 | 61.12 | 15.9 | 9.75 | 26.78 | 61.95 | 59.85 |
| Enterprise Value (EV) 1 | -15.51 | 11.24 | -78.33 | -81.94 | 0.0913 | -0.7089 |
| P/E ratio | 60.7 x | 7.71 x | 2.35 x | 10.7 x | 11.1 x | 127 x |
| Yield | - | - | - | - | - | - |
| Capitalization / Revenue | 5.64 x | 1.93 x | 0.98 x | 4.88 x | 7.85 x | 20.3 x |
| EV / Revenue | -1.43 x | 1.37 x | -7.86 x | -14.9 x | 0.01 x | -0.24 x |
| EV / EBITDA | -2.02 x | 4.33 x | -14.8 x | -24.5 x | 0.02 x | -0.73 x |
| EV / FCF | -1.21 x | -0.16 x | -1.32 x | -120 x | 0.03 x | -7.49 x |
| FCF Yield | -82.8% | -629% | -75.8% | -0.84% | 3,007% | -13.3% |
| Price to Book | 0.6 x | 0.15 x | 0.09 x | 0.24 x | 0.54 x | 0.52 x |
| Nbr of stocks (in thousands) | 1,500 | 1,500 | 1,500 | 1,500 | 1,500 | 1,500 |
| Reference price 2 | 40.75 | 10.60 | 6.500 | 17.85 | 41.30 | 39.90 |
| Announcement Date | 9/6/18 | 7/28/19 | 8/20/20 | 8/3/21 | 8/12/22 | 8/21/23 |
1INR in Million2INR
Estimates
Income Statement Evolution (Annual data)
| Fiscal Period: Maart | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 |
|---|---|---|---|---|---|---|
| Net sales 1 | 10.85 | 8.225 | 9.968 | 5.483 | 7.889 | 2.951 |
| EBITDA 1 | 7.668 | 2.594 | 5.306 | 3.347 | 3.838 | 0.9713 |
| EBIT 1 | 7.634 | 2.547 | 5.074 | 3.108 | 3.649 | 0.8403 |
| Operating Margin | 70.38% | 30.96% | 50.91% | 56.68% | 46.26% | 28.47% |
| Earnings before Tax (EBT) 1 | 7.634 | 2.546 | 4.941 | 3.107 | 3.649 | 0.732 |
| Net income 1 | 1.006 | 2.063 | 4.152 | 2.501 | 5.599 | 0.473 |
| Net margin | 9.28% | 25.08% | 41.65% | 45.61% | 70.98% | 16.03% |
| EPS 2 | 0.6709 | 1.375 | 2.768 | 1.667 | 3.733 | 0.3154 |
| Free Cash Flow 1 | 12.84 | -70.68 | 59.41 | 0.6843 | 2.746 | 0.0946 |
| FCF margin | 118.42% | -859.23% | 596.02% | 12.48% | 34.81% | 3.2% |
| FCF Conversion (EBITDA) | 167.49% | - | 1,119.75% | 20.44% | 71.54% | 9.74% |
| FCF Conversion (Net income) | 1,276.27% | - | 1,431% | 27.36% | 49.04% | 19.99% |
| Dividend per Share | - | - | - | - | - | - |
| Announcement Date | 9/6/18 | 7/28/19 | 8/20/20 | 8/3/21 | 8/12/22 | 8/21/23 |
1INR in Million2INR
Estimates
Balance Sheet Analysis
| Fiscal Period: Maart | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 |
|---|---|---|---|---|---|---|
| Net Debt 1 | - | - | - | - | - | - |
| Net Cash position 1 | 76.6 | 4.66 | 88.1 | 109 | 61.9 | 60.6 |
| Leverage (Debt/EBITDA) | - | - | - | - | - | - |
| Free Cash Flow 1 | 12.8 | -70.7 | 59.4 | 0.68 | 2.75 | 0.09 |
| ROE (net income / shareholders' equity) | 1% | 2.02% | 3.94% | 2.3% | 4.97% | 0.41% |
| ROA (Net income/ Total Assets) | 4.55% | 1.54% | 2.97% | 1.76% | 2.01% | 0.45% |
| Assets 1 | 22.12 | 134 | 140 | 141.7 | 278.9 | 104.9 |
| Book Value Per Share 2 | 67.50 | 68.90 | 71.60 | 73.30 | 77.00 | 77.30 |
| Cash Flow per Share 2 | 51.10 | 3.110 | 58.70 | 72.50 | 4.570 | 3.710 |
| Capex | - | - | - | - | - | - |
| Capex / Sales | - | - | - | - | - | - |
| Announcement Date | 9/6/18 | 7/28/19 | 8/20/20 | 8/3/21 | 8/12/22 | 8/21/23 |
1INR in Million2INR
Estimates
EPS & Dividend
Year-on-year evolution of the PER
Change in Enterprise Value/EBITDA
- Stock Market
- Equities
- CHEMOPH6 Stock
- Financials Chemo Pharma Laboratories Limited
